TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.
Eye (London, England)
View this publicationEye (London, England)
View this publicationScientific reports
View this publicationDiagnostics (Basel, Switzerland)
View this publicationMolecular cancer
View this publicationCardiovascular research
View this publicationNature communications
View this publicationScientific reports
View this publicationFrontiers in immunology
View this publicationNeurology(R) neuroimmunology & neuroinflammation
View this publicationChemMedChem
View this publication